Aratana Therapeutics Inc. (NASDAQ:PETX)’s share price fell 0.8% on Wednesday after an insider sold shares in the company. The company traded as low as $9.82 and last traded at $10.22, with a volume of 766,019 shares trading hands. The stock had previously closed at $10.30.

Specifically, insider Ernst Heinen sold 10,000 shares of Aratana Therapeutics stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $10.00, for a total transaction of $100,000.00. Following the completion of the sale, the insider now directly owns 115,494 shares of the company’s stock, valued at approximately $1,154,940. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Peter Steven St sold 50,000 shares of Aratana Therapeutics stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $9.25, for a total transaction of $462,500.00. Following the sale, the insider now directly owns 642,793 shares of the company’s stock, valued at $5,945,835.25. The disclosure for this sale can be found here. Insiders own 6.70% of the company’s stock.

A number of research firms have recently issued reports on PETX. Barclays PLC dropped their price objective on shares of Aratana Therapeutics from $15.00 to $11.00 and set an “overweight” rating for the company in a report on Thursday, August 11th. Credit Suisse Group AG reissued a “buy” rating and issued a $11.00 price target on shares of Aratana Therapeutics in a research note on Wednesday, August 10th. Jefferies Group began coverage on shares of Aratana Therapeutics in a research note on Friday, August 19th. They issued a “buy” rating and a $13.00 price target for the company. William Blair reissued an “outperform” rating on shares of Aratana Therapeutics in a research note on Wednesday, August 17th. Finally, Lake Street Capital reissued a “buy” rating and issued a $15.00 price target on shares of Aratana Therapeutics in a research note on Tuesday, September 6th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $11.28.

The stock’s market cap is $355.57 million. The stock’s 50-day moving average price is $9.24 and its 200-day moving average price is $7.30.

Aratana Therapeutics (NASDAQ:PETX) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.61 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.37. The company earned $38.05 million during the quarter, compared to analysts’ expectations of $15.14 million. Aratana Therapeutics had a negative net margin of 166.67% and a negative return on equity of 17.53%. During the same period last year, the company posted ($0.23) earnings per share. On average, equities analysts expect that Aratana Therapeutics Inc. will post ($0.77) EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the stock. Franklin Resources Inc. boosted its position in Aratana Therapeutics by 23.7% in the first quarter. Franklin Resources Inc. now owns 5,421,549 shares of the biopharmaceutical company’s stock valued at $29,927,000 after buying an additional 1,037,646 shares during the last quarter. BlackRock Fund Advisors boosted its position in Aratana Therapeutics by 8.1% in the second quarter. BlackRock Fund Advisors now owns 1,308,679 shares of the biopharmaceutical company’s stock valued at $8,271,000 after buying an additional 98,007 shares during the last quarter. Vanguard Group Inc. boosted its position in Aratana Therapeutics by 20.4% in the second quarter. Vanguard Group Inc. now owns 1,270,655 shares of the biopharmaceutical company’s stock valued at $8,031,000 after buying an additional 214,900 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in Aratana Therapeutics by 5.1% in the second quarter. Massachusetts Financial Services Co. MA now owns 971,935 shares of the biopharmaceutical company’s stock valued at $6,143,000 after buying an additional 47,102 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its position in Aratana Therapeutics by 14.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 869,516 shares of the biopharmaceutical company’s stock valued at $5,495,000 after buying an additional 109,243 shares during the last quarter. 85.56% of the stock is owned by institutional investors.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

5 Day Chart for NASDAQ:PETX

Receive News & Stock Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related stocks with our FREE daily email newsletter.